Pharmacological and RNA interference-mediated inhibition of p300 specifically impairs AE/AE9a-induced transcriptional activation and leukemogenesis, but does not affect the development of MLL–AF9-induced leukemia. This evidence concerns the gene EP300 and leukemia.